TapImmune Inc. (OTCMKTS:TPIV) Drops Again, Gets a Lone Pump

Friday brought another double-digit red session for TapImmune Inc. (OTCMKTS:TPIV). The company was trading at around $1.50 just a few sessions ago but a streak of red sessions sliced it down to its last close at $1.15. On Friday TPIV dropped another 10% on heavy volume of 1.7 million shares.

The reason why TPIV reversed in the first place does not seem to be connected with any negative filings or developments with the company. On the contrary, TPIV last announced very promising results from Phase 1 trials conducted on a group of female patients who had already undergone operative and chemo therapy breast cancer treatment. TapImmune announced 19 out of 20 of those patients registered a positive immune response after multiple introductions of a vaccine.

However, TPIV‘s climb that took it from a humble $0.20 per share in April to the recent highs of a dollar and a half per share took place a little too quickly for the stock’s own good. TPIV was oversold for weeks on end before it started slipping. Where a healthy pullback stops and outright disaster begins is something every trader should decide for themselves, depending on their own calculations and risk tolerance. So far, TPIV has slipped 23% from its highest close last week.

Somewhat disconcertingly, there is now at least one paid pump email targeting TPIV that is padded with a considerable monetary compensation. Even though there were a small number of pump emails before, none were really compensated with any amount of money worth noticing and were one-day drive-by deals. This new email states it is a one-day promo affair as well but is compensated with $50,000 according to its disclaimer.

When an unnamed third party is willing to part with $50 thousand to promote a certain stock, investors may do well to tread with extra care, regardless of the company’s prior chart performance.